Theeffectiveness of intracavernous autologous platelet-rich plasma in the treatment of erectile dysfunction
- Authors: Chalyj ME1, Grigorjan VA1, Epifanova MV2, Krasnov AO1
-
Affiliations:
- Sechenov First Moscow State Medical University
- Research Institute of Uronephrology and Human Reproductive Health
- Issue: No 4 (2015)
- Pages: 76-79
- Section: Articles
- URL: https://journals.eco-vector.com/1728-2985/article/view/281801
- ID: 281801
Cite item
Open Access
Access granted
Subscription or Fee Access
Abstract
This article deals with using autologous platelet-rich plasma (APRP) as a new treatment for erectile dysfunction in men. In recent years there was a significant interest in regenerative medicine technology due to its high effectiveness with a good safety and low cost. Currently APRP has been used successfully in various fields of medicine (surgery, traumatology and orthopedics, sports medicine, cosmetics). However, until now there have been no studies consistent with evidence-based medicine verifying the effectiveness and long-term results of APRP application for ED treatment. This article presents the results of a clinical study on the use of APRP in men with ED with a comparative effectiveness analysis of different ways of APRP administration and in combination with PDE5 inhibitors. Possible mechanisms of action of APRP in restoring erectile function are discussed.
About the authors
M E Chalyj
Sechenov First Moscow State Medical UniversitySechenov First Moscow State Medical University
V A Grigorjan
Sechenov First Moscow State Medical UniversitySechenov First Moscow State Medical University
M V Epifanova
Research Institute of Uronephrology and Human Reproductive HealthResearch Institute of Uronephrology and Human Reproductive Health
A O Krasnov
Sechenov First Moscow State Medical UniversitySechenov First Moscow State Medical University
References
- Пушкарь Д.Ю., Камалов А.А., Аль-Шукри С.Х., Еркович А.А., Коган М.И., Павлов В.Н., Журавлев В.Н., Берников А.Н. Эпидемиологическое исследование распространенности эректильной дисфункции в Российской Федерации. Уральский медицинский журнал. 2012;3:75-79.
- Ferguson J.E. Phosphodiesterase type 5 inhibitors as a treatment for erectile dysfunction: Current information and new horizons. AJU. 2013;11(3):222-229.
- Fagelman E., Fagelman A., Shabsigh R. Efficacy, safety, and use of sildenafil in urologic practice. Urology. 2001;57:1141-1144.
- Gonzalgo M.L., Brotzman M., Trock B.J., GeringerA.M., BurnettA.L., Jarow J.P. Clinical efficacy of sildenafil citrate and predictors of long-term response. J. Urol. 2003;170:503-506.
- Souverein P.C., Egberts A. C., Meuleman E.J., Urquhart J., Leufkens H. G. Incidence and determinants of sildenafil (dis) continuation: the Dutch cohort of sildenafil users. Int. J. Impot. Res. 2002;14:259-265.
- Eardley I., Rosen R., Fisher W, Niederberger C, Sand M. Attitudes toward treatment of erectile dysfunction: results from the MALES study. Eur. Urol. 2003;42(2).
- Глыбочко П.В., Чалый М.Е., Епифанова М.В., Краснов А.О. Применение аутоплазмы, обогащенной тромбоцитарными факторами роста, в лечении эректильной дисфункции. Урология. 2015;1:100-103.
- Lee J.W., Kwon O.H., Kim T.K., Cho Y.K., Choi K.Y., Chung H.Y., Cho B.C., Yang J.D., Shin J.H. Platelet-Rich Plasma: Quantitative Assessment ofGrowth Factor Levels and Comparative Analysis ofActi- vated and Inactivated Groups. Arch. Plast. Surg. 2013;40:530-535. 9.
- MarxR.E., CarlsonE.R., Eichstaedt R.M., SchimmeleS.R., Strauss J.E., Georgeff K.R. Platelet-rich plasma: growth factor enhancement for bone grafts. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. 1998;85:638-646. 10.
- Weiser L, Bhargava M, Attia E., Torzilli P.A. Effect of serum and platelet-derived growth factor on chondrocytes grown in collagen gels. Tissue Eng. 1999;5:533e44.
- Чалый М.Е., Епифанова М.В. Способ лечения эректильной дисфункции, патент РФ № 2514639 от 27.04.2014.
Supplementary files
